Friday February 08, 2013

Dynamic sales growth: +39% (+34% at constant exchange rate) with a growth of +40% for kits'sales

QIAGEN Marseille, subsidiary of the QIAGEN Group, previously IPSOGEN (Alternext - FR0010626028 - ALIPS), a cancer profiler that develops, manufactures and markets molecular diagnostic tests for leukemia and cancer, today announces its consolidated revenues for the fiscal year 2012.

Total revenue for the year ended December 31st, 2012 reached 13.2 M€, compared with 9.5 M€ in 2011, an increase of +39% over last year (+34% at constant foreign exchange rate).

See press release

distributed by